Genetic variants in XRRC5 may predict development of venous thrombotic events in myeloma patients on thalidomide

Blood. 2009 May 28;113(22):5691-2. doi: 10.1182/blood-2009-03-211177.
No abstract available

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't
  • Comment

MeSH terms

  • Angiogenesis Inhibitors / therapeutic use
  • Case-Control Studies
  • DNA Helicases / genetics*
  • Genetic Predisposition to Disease
  • Humans
  • Ku Autoantigen
  • Linkage Disequilibrium
  • Multiple Myeloma / complications
  • Multiple Myeloma / drug therapy*
  • Multiple Myeloma / genetics
  • Polymorphism, Single Nucleotide* / physiology
  • Prognosis
  • Thalidomide / therapeutic use*
  • Venous Thrombosis / diagnosis*
  • Venous Thrombosis / etiology
  • Venous Thrombosis / genetics

Substances

  • Angiogenesis Inhibitors
  • Thalidomide
  • DNA Helicases
  • XRCC5 protein, human
  • Ku Autoantigen